{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:28:59Z","timestamp":1781299739740,"version":"3.54.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003482","name":"Department of Education of Hebei Province","doi-asserted-by":"publisher","award":["QN2024003"],"award-info":[{"award-number":["QN2024003"]}],"id":[{"id":"10.13039\/501100003482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009076","name":"University of Science and Technology of China","doi-asserted-by":"publisher","award":["ZD-YG-202415"],"award-info":[{"award-number":["ZD-YG-202415"]}],"id":[{"id":"10.13039\/501100009076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404152"],"award-info":[{"award-number":["82404152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["H2023209084"],"award-info":[{"award-number":["H2023209084"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.coi.2025.102559","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:14:50Z","timestamp":1746058490000},"page":"102559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advances in genetic\u2013immunological targeted therapies for psoriasis"],"prefix":"10.1016","volume":"94","author":[{"given":"Qi","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8499-5353","authenticated-orcid":false,"given":"Liangdan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102559_sbref1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","article-title":"\"Autoinflammatory psoriasis\"-genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102559_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102559_bib3","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202345","article-title":"Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis","volume":"218","author":"Nakamizo","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102559_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi8823","article-title":"TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy","volume":"6","author":"Gupta","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2025.102559_bib5","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.it.2021.09.005","article-title":"ROR\u03b3t protein modifications and IL-17-mediated inflammation","volume":"42","author":"Kumar","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coi.2025.102559_sbref6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/bjd\/ljad481","article-title":"The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"190","author":"Alabas","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib7","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102559_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15228","article-title":"Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study","volume":"35","author":"Narcisi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102559_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/2589977513666210707114520","article-title":"IL-23\/Th17 axis: a potential therapeutic target of psoriasis","volume":"14","author":"Sharma","year":"2022","journal-title":"Curr Drug Res Rev"},{"key":"10.1016\/j.coi.2025.102559_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","article-title":"HLA-Cw1 and psoriasis","volume":"22","author":"Huang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5919150","article-title":"Enhanced wound healing- and inflammasome-associated gene expression in TNFAIP3-interacting protein 1- (TNIP1-) deficient HaCaT keratinocytes parallels reduced reepithelialization","volume":"2020","author":"Shamilov","year":"2020","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.coi.2025.102559_bib13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/ijms23031337","article-title":"Genome editing using CRISPR-Cas9 and autoimmune diseases: a comprehensive review","volume":"23","author":"Lee","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102559_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102559_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2014.07.010","article-title":"The panoply of \u03b1\u03b2T cells in the skin","volume":"76","author":"Nomura","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coi.2025.102559_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8652","article-title":"NF-\u03baB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis","volume":"6","author":"Yan","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102559_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102559_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63613-4","article-title":"Cigarette smoking induces human CCR6+Th17 lymphocytes senescence and VEGF-A secretion","volume":"10","author":"Baskara","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102559_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coi.2025.102559_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Riol-Blanco","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coi.2025.102559_bib22","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3390\/ijms18122650","article-title":"The immunogenetics of psoriasis and implications for drug repositioning","volume":"18","author":"Xu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102559_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102559_sbref25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","article-title":"FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis","volume":"92","author":"Ferris","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib26","first-page":"127","article-title":"Anti-psoriasis molecular targets and active components discovery of Optimized Yinxieling Formula via affinity-purified strategy","volume":"22","author":"Wang","year":"2024","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.coi.2025.102559_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coi.2025.102559_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jid.2023.04.005","article-title":"Assessment of treatment-relevant immune biomarkers in psoriasis and atopic dermatitis: toward personalized medicine in dermatology","volume":"143","author":"Mortlock","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100103","article-title":"The potential of CRISPR-guided therapies in the dermatology clinic","volume":"2","author":"Bhat","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.coi.2025.102559_bib31","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2025.102559_bib32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)\u201117 and IL\u201123 inhibitors for the treatment of psoriasis: a retrospective multi\u2011country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102559_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s12915-020-00779-3","article-title":"Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31","volume":"18","author":"Ray-Jones","year":"2020","journal-title":"BMC Biol"},{"key":"10.1016\/j.coi.2025.102559_bib35","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coi.2025.102559_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110242","article-title":"Single-cell technologies in psoriasis","volume":"264","author":"Cui","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102559_bib37","article-title":"Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102559_bib38","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.3390\/jcm10194307","article-title":"Role of Janus kinase inhibitors in therapy of psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142\u0105bowska","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2025.102559_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-020-00466-9","article-title":"Gut-brain-skin axis in psoriasis: a review","volume":"11","author":"Chen","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102559_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/ijd.ijd_167_24","article-title":"Biomarkers in psoriasis: the future of personalised treatment","volume":"69","author":"Kar","year":"2024","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15759","article-title":"Latest combination therapies in psoriasis: narrative review of the literature","volume":"35","author":"Diotallevi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102559_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00100","article-title":"Artificial intelligence applications in dermatology: where do we stand?","volume":"7","author":"Gomolin","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2025.102559_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11760-023-02722-9","article-title":"Automated detection and classification of psoriasis types using deep neural networks from dermatology images","volume":"18","author":"Rashid","year":"2024","journal-title":"Signal Image Video Process"},{"key":"10.1016\/j.coi.2025.102559_sbref44","article-title":"Large-scale proteome profiling identifies biomarkers associated with suspected neurosyphilis diagnosis","volume":"11","author":"Li","year":"2024","journal-title":"Adv Sci"},{"key":"10.1016\/j.coi.2025.102559_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102559_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.coi.2025.102559_bib47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102559_bib48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","article-title":"Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","volume":"90","author":"Warren","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102559_sbref49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.coi.2025.102559_bib50","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102559_sbref51","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2025.102559_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5114\/ada.2019.85641","article-title":"Evaluation of selected mechanisms of immune tolerance in psoriasis","volume":"36","author":"Owczarczyk-Saczonek","year":"2019","journal-title":"Post Dermatol Alergol"},{"key":"10.1016\/j.coi.2025.102559_bib53","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2025.102559_bib54","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102559_sbref55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177521","article-title":"Alterations of gut microbiota for the onset and treatment of psoriasis: a systematic review","volume":"998","author":"Xue","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coi.2025.102559_bib56","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102559_bib57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40257-018-0366-5","article-title":"Targeting the IL-23\/IL-17 pathway in psoriasis: the search for the good, the bad and the ugly","volume":"19","author":"Mylle","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102559_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt.688","article-title":"Recent advances in small molecule and biological therapeutic approaches in the treatment of psoriasis","volume":"102","author":"Turbeville","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coi.2025.102559_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","author":"L\u00f6scher","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:28:43Z","timestamp":1777782523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":59,"alternative-id":["S0952791525000354"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102559","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in genetic\u2013immunological targeted therapies for psoriasis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102559"}}